Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX +2.21%14 Debt-to-EBITDA is -0.02 as of Dec. 2025. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Nasus Pharma ranks worse than 146842.73% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nasus Pharma's Debt-to-EBITDA or its related term are showing as below:
NSRX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.14 Med: -1.2 Max: -0.02
Current: -0.02
During the past 4 years, the highest Debt-to-EBITDA Ratio of Nasus Pharma was -0.02. The lowest was -2.14. And the median was -1.20.
NSRX's Debt-to-EBITDA is ranked worse than 100% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSRX: -0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nasus Pharma Debt-to-EBITDA Related Terms
Nasus Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nasus Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSRX vs MIRA, SCLX, MDCX: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Nasus Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Nasus Pharma (NSRX) has a Debt-to-EBITDA of -0.02 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nasus Pharma. According to the industry distribution chart, Nasus Pharma ranks #999999 out of 681 companies in the Drug Manufacturers industry.
Is Nasus Pharma's Debt-to-EBITDA too high?
Nasus Pharma's current Debt-to-EBITDA is -0.02. Based on the distribution chart, Nasus Pharma ranks #999999 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's Debt-to-EBITDA compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #999999 out of 681 companies for Debt-to-EBITDA. This places Nasus Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nasus Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current Debt-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current Debt-to-EBITDA of -0.02. The current Debt-to-EBITDA is -0.02. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current Debt-to-EBITDA is -0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
